Cerity Partners LLC Sells 13,619 Shares of GE HealthCare Technologies Inc. $GEHC

Cerity Partners LLC cut its holdings in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 3.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 359,951 shares of the company’s stock after selling 13,619 shares during the quarter. Cerity Partners LLC owned 0.08% of GE HealthCare Technologies worth $29,523,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Laurel Wealth Advisors LLC bought a new position in shares of GE HealthCare Technologies during the fourth quarter worth approximately $26,000. Optima Capital LLC bought a new position in shares of GE HealthCare Technologies during the fourth quarter worth approximately $27,000. Godfrey Financial Associates Inc. bought a new position in shares of GE HealthCare Technologies during the fourth quarter worth approximately $27,000. Montag A & Associates Inc. increased its holdings in shares of GE HealthCare Technologies by 105.4% during the fourth quarter. Montag A & Associates Inc. now owns 341 shares of the company’s stock worth $28,000 after purchasing an additional 175 shares during the period. Finally, Maseco LLP bought a new position in shares of GE HealthCare Technologies during the fourth quarter worth approximately $29,000. 82.06% of the stock is owned by institutional investors.

Insider Transactions at GE HealthCare Technologies

In related news, CEO Peter J. Arduini bought 4,169 shares of the business’s stock in a transaction on Thursday, April 30th. The shares were purchased at an average price of $59.92 per share, for a total transaction of $249,806.48. Following the completion of the transaction, the chief executive officer directly owned 259,424 shares of the company’s stock, valued at approximately $15,544,686.08. This represents a 1.63% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director Kevin Lobo bought 10,000 shares of the business’s stock in a transaction on Friday, May 22nd. The stock was bought at an average price of $64.18 per share, for a total transaction of $641,800.00. Following the transaction, the director directly owned 14,363 shares of the company’s stock, valued at approximately $921,817.34. This represents a 229.20% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last three months, insiders have acquired 21,847 shares of company stock valued at $1,361,355. Corporate insiders own 0.36% of the company’s stock.

GE HealthCare Technologies Stock Performance

NASDAQ GEHC opened at $63.76 on Thursday. The company has a current ratio of 1.22, a quick ratio of 0.95 and a debt-to-equity ratio of 0.95. The firm has a market capitalization of $29.00 billion, a price-to-earnings ratio of 15.25, a P/E/G ratio of 1.49 and a beta of 0.74. The firm’s 50 day simple moving average is $66.59 and its 200 day simple moving average is $75.36. GE HealthCare Technologies Inc. has a 1 year low of $58.75 and a 1 year high of $89.77.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its earnings results on Wednesday, April 29th. The company reported $0.99 earnings per share for the quarter, missing analysts’ consensus estimates of $1.07 by ($0.08). GE HealthCare Technologies had a net margin of 9.10% and a return on equity of 20.46%. The company had revenue of $5.13 billion during the quarter, compared to analyst estimates of $5.04 billion. During the same quarter in the prior year, the business earned $1.01 EPS. The business’s quarterly revenue was up 7.4% on a year-over-year basis. GE HealthCare Technologies has set its FY 2026 guidance at 4.800-5.000 EPS. As a group, research analysts expect that GE HealthCare Technologies Inc. will post 4.89 earnings per share for the current fiscal year.

Analysts Set New Price Targets

GEHC has been the topic of several recent research reports. BNP Paribas Exane lowered their target price on shares of GE HealthCare Technologies from $95.00 to $88.00 in a report on Friday, May 1st. The Goldman Sachs Group reaffirmed a “neutral” rating on shares of GE HealthCare Technologies in a report on Monday. Wall Street Zen cut shares of GE HealthCare Technologies from a “buy” rating to a “hold” rating in a report on Saturday, March 21st. Argus lowered their target price on shares of GE HealthCare Technologies from $95.00 to $80.00 and set a “buy” rating on the stock in a report on Tuesday, May 19th. Finally, HSBC reduced their price target on shares of GE HealthCare Technologies from $100.00 to $90.00 in a research report on Thursday, April 30th. Nine investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, GE HealthCare Technologies has a consensus rating of “Moderate Buy” and an average price target of $80.21.

About GE HealthCare Technologies

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.